People: Infinity Pharmaceuticals Inc (INFI.O)

INFI.O on Nasdaq

12.95USD
20 Oct 2014
Price Change (% chg)

$0.17 (+1.33%)
Prev Close
$12.78
Open
$12.50
Day's High
$13.19
Day's Low
$12.47
Volume
411,224
Avg. Vol
996,478
52-wk High
$18.35
52-wk Low
$8.40

Search Stocks

Fyfe, Gwendolyn 

Brief Biography

Dr. Gwendolyn A. Fyfe, M.D., serves as Independent Director of Infinity Pharmaceuticals Inc., since March 8, 2012. From 1997 to 2009, Dr. Fyfe held various positions with Genentech, Inc. (now a member of the Roche Group), a publicly traded biopharmaceutical company, including Vice President, Oncology Development; Vice President, Avastin® Franchise Team; as well as the honorary title of Senior Staff Scientist. Dr. Fyfe played an important role in the development of Genentech’s approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Dr. Fyfe sat on the development oversight committee for all of Genentech’s products and participated in the Research Review Committee that moved products from research into clinical development. Since leaving Genentech in 2009, Dr. Fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies. Dr. Fyfe has served on the board of directors of Array BioPharma, Inc., a publicly traded biopharmaceutical company, since January 2012; Igenica, Inc., a privately held biopharmaceuticals company, since December 2013; and previously served on the board of Pharmacyclics, Inc., a publicly traded biopharmaceutical company, during the last five years. Dr. Fyfe is a recognized oncology expert in the broader oncology community and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. She received her M.D. from Washington University School of Medicine and is a board certified pediatric oncologist.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Adelene Perkins

3,861,160

Lawrence Bloch

1,090,810

Julian Adams

2,651,310

Vito Palombella

1,787,960

David Roth

--

Norman Selby

--
As Of 30 Dec 2013
Search Stocks